Pharmaceutical Product Development, LLC (PPD) is cited in a CenterWatch survey for innovative technology, patient recruitment and site activation.
Pharmaceutical Product Development, LLC (PPD) announced it has been ranked one of the world’s best contract research organisations (CROs) in sustaining strong relationships with investigative sites to promote efficiency, quality and patient safety in clinical research.
Research sites gave PPD excellent ratings on a series of key success indicators in the CenterWatch 2015 Global Site Survey, published today in CenterWatch Monthly. The survey measured the quality of working relationships between CROs and investigative sites conducting clinical trials in developing life-changing medical treatments. The results build on PPD’s recognition in CenterWatch’s previous survey as having the CRO industry’s best reputation.
“PPD purposefully fosters site relationships that enable investigators to more easily participate successfully in clinical trials, while leveraging our global capabilities, a technology advantage, innovative processes and talented people to reduce drug development time and cost for biopharma clients,” said Paul Colvin, PPD’s executive vice president for global clinical development. “With the growing complexity of clinical trials, PPD is committed to providing sites and clients the global resources required to streamline research to more efficiently deliver positive outcomes for patients.”
More than four of every five survey respondents rated PPD as excellent or good, with nearly 50 percent rating PPD as excellent. Both results were increases from the last CenterWatch site survey. PPD ranked among the top three CROs in 26 of the 37 relationship attributes that 2015 survey respondents were asked to judge.
PPD received high scores for excellence in key areas that sites rated as the most important to successful study conduct: professional, knowledgeable and well-trained monitors/clinical research associates; having organized and prepared study support; easily accessible staff for escalation of issues and providing timely and appropriate resolution; and professional medical staff in clinical operations.
In addition, PPD had high scores for excellence in site management attributes including providing patient recruitment planning and support; clear initiation visits and training; support of initiatives to help sites build stronger relationships with study volunteers; and using technology to make processes more efficient. PPD also received high scores for overall project support; study monitoring support; an efficient query handling process and effectively using communication technologies.
Multiple strategic initiatives underpin PPD’s successful site relationships. For instance, PPD’s site intelligence and activation (SIA) group deploys innovative process improvements toward gaining industry-leading cycle times that offer a competitive advantage in strategic project planning, site activation and, ultimately, enrolment. Since the SIA model was launched in 2012, PPD has achieved a greater than 25 percent reduction in mean and median site activation cycle times (site qualified to site active) and a 15 percent reduction in start-up cycle times for the critical measure of final protocol to first patient in.
In addition, the company’s real-time data analytics platform, Preclarus™, combines the process, people and organization of PPD to provide an unprecedented view into clinical trial data and operations. And PPD’s Acurian provides industry-leading services that accelerate patient enrolment and support strategies for data-driven feasibility, site selection and enrolment delivery.
CenterWatch’s 2015 Global Site Survey was conducted from October 2014 through early January 2015. More than 72 percent of the 1,900 clinical research professionals who completed the survey were from North America and Europe, according to CenterWatch, and more than 65 percent of respondents were investigators.